Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Lin, Chih-Langa; b; c; d | Chien, Rong-Nana; b; c; d | Chen, Li-Weia; b; c; d | Chu, Yu-Deb; * | Yeh, Chau-Tingb; c; *
Affiliations: [a] Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan | [b] Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan | [c] College of Medicine, Chang Gung University, Taoyuan, Taiwan | [d] Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
Correspondence: [*] Corresponding authors: Yu-De Chu and Chau-Ting Yeh, Liver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. Tel.: +886 3 3281200 ext 7773; E-mail: yudechu@cgmh.org.twandchauting@cgmh.org.tw.
Abstract: BACKGROUND: Sorafenib and lenvatinib are tyrosine kinase inhibitors widely used in the targeted therapy to treat advanced hepatocellular carcinoma (aHCC). The GALNT14-rs9679162 genotype is a predictor of therapeutic outcome in multiple gastrointestinal cancers. OBJECTIVE: To investigate the predictive role of the GALNT14-rs9679162 genotype in aHCC treated with sorafenib or lenvatinib. METHODS: Totally 350 real-world patients with aHCC received sorafenib or lenvatinib were enrolled for GALNT14-rs9679162 genotyping and outcome analysis. Kaplan-Meier and Cox regression analysis were conducted to evaluate therapeutic outcomes. Cell-based assays were performed to determine the underlying mechanism. RESULTS: Kaplan-Meier and Cox regression analysis showed that the “GG” genotype was not associated with overall survival (OS) when all patients were included. However, it was associated with shorter OS in specific clinical subgroups, including anti-hepatitis C virus antibody-positive (n= 108; P= 0.005) and hepatitis B surface antigen-negative (n= 117; P= 0.002) patients. Intriguingly, hepatitis B virus X protein trans-suppressed the GALNT14 promoter, thereby reducing the elevated expression of GALNT14 in hepatoma cells, which partially contributed to the inability of the GALNT14-rs9679162 genotypes to predict the outcome of hepatitis B-related HCC. Finally, by analyzing the outcomes of 52 patients with aHCC treated with lenvatinib, patients with the “GG” genotype were associated with a favorable/shorter time-to-response (P= 0.013). CONCLUSIONS: The GALNT14-rs9679162 “GG” genotype predicted shorter OS in patients with HBsAg-negative aHCC treated with sorafenib, but predicted a favorable response in all patients with aHCC treated with lenvatinib.
Keywords: Single nucleotide polymorphism, Rs9679162 genotype, advanced hepatocellular carcinoma (HCC), genetic biomarker and overall survival
DOI: 10.3233/CBM-220042
Journal: Cancer Biomarkers, vol. 36, no. 3, pp. 251-266, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl